For adult and pediatric patients with hemophilia A
AFSTYLA, with twice-weekly dosing available, delivers long-lasting bleed protection using a novel single-chain design
Enhanced von Willebrand
factor affinity extends time
in circulation †1
† As demonstrated in pre-clinical animal studies.
Have a CSL Behring representative contact you or sign up for updates and information about AFSTYLA
Call AFSTYLA ConnectSM at 1-800-676-4266
A Case Manager is standing by—Monday through Friday, 8am to 8pm ET—to provide you detailed information about services available to your patients.
Reference: 1. Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134(1):125-131.